Real-world Retrospective Study of RSV Hospital Care Burden, HCRU, and Costs in a Multi-country Hospital Database (REACH)

29/05/2026
29/05/2026
EU PAS number:
EUPAS1000000941
Study
Ongoing
Study identification

EU PAS number

EUPAS1000000941

Study ID

1000000941

Official title and acronym

Real-world Retrospective Study of RSV Hospital Care Burden, HCRU, and Costs in a Multi-country Hospital Database (REACH)

DARWIN EU® study

No

Study countries

Netherlands
Spain
United Kingdom

Study description

Respiratory syncytial virus (RSV) is a leading cause of respiratory infections, particularly in infants. Different countries have implemented various immunization options, including monoclonal antibodies and maternal vaccines. In this context, the Real-world Retrospective Study of RSV Hospital Care Burden, HCRU, and Costs in a Multi-country Hospital Database (REACH) study aims to quantify the reduction in burden amongst infants of RSV-related hospital care across Spain (ES), the United Kingdom (UK) and the Netherlands (NL). Monoclonal antibody immunization, Nirsevimab, was introduced in Spain for the 23/24 season, in NL in the 25/26 seasons and maternal immunization, RSV-vaccine, was introduced in UK for the 24/25 season. This observational, retrospective study utilizes administrative and microbiology data covering RSV seasons from 2022-2026. The study reports ICD-10 coded Lower Respiratory Tract Infections (LRTI) and RSV-LRTI hospital admissions, length of stay, Intensive Care Unit (ICU) admissions, laboratory-confirmed cases, direct hospitalization costs, and post-discharge healthcare resource utilization (HCRU) by country, with stratification by season, age and risk groups, and period of birth relative to the RSV season.

Study status

Ongoing
Research institutions and networks

Institutions

Sanofi
First published:
01/02/2024
Institution
LOGEX Life Sciences
Netherlands
First published:
04/11/2022
Institution Non-Pharmaceutical company ENCePP partner

Contact details

Jeroen Geurtsen

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Sanofi and AstraZeneca
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable